Nanolcoholic fatty liver disease

Global Metabolic Profiling: Clinical Applications

Volumn , Issue , 2014, Pages 110-122

  Alonso, Cristina ^b   Mato, José M ^a  

^a CIC BIOGUNE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FATTY LIVER DISEASE;

EID: 84907190808     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4155/EBO.13.392     Document Type: Chapter

References (18)

1. Psychogios N, Hau DD, Peng J et al. The human serum metabolome. PLoS ONE 6(2), e16957 (2011).
2. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346(16), 1221-1231 (2002).
3. Puri P, Baillie RA, Wiest MM et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46(4), 1081-1090 (2007).
4. Kotronen A, Seppänen- Laakso T, Westerbacka J et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 58, 203-208 (2009).
5. García-Cañaveras JC, Donato MT, Castell JV et al. A comprehensive untargeted metabonomic analysis of human steatotic liver tissue by RP and HILIC chromatography coupled to mass spectrometry reveals important metabolic alterati ns. J. Proteome Res. 10(10), 4825-4834 (2011).
6. Jungermann K, Kietzmann T. Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology 31(2), 255-260 (2000).
7. Debois D, Bralet MP, Le Naour F et al. In situ lipidomic analysis of nonalcoholic fatty liver by cluster TOF-SIMS imaging. Anal. Chem. 81(8), 2823-2831 (2009).
8. Le Naour F, Bralet MP, Debois D et al. Chemical imaging on liver steatosis using synchrotron Infrared and ToF-SIMS micro- spectroscopies. PLoS ONE 4(10), e7408 (2009).
9. Wattacheril J, Seeley EH, Angel P et al. Differential intra hepatic phospholipid zonation in simple steatosis and nonalcoholic steatohepatitis. PLoS ONE 8(2), e87165 (2013).
10. Martinez-Uña M, Varela-rey M, Cano A et al. Excess S-adenosylmethionine reroutes phosphatidyl- ethanolamine towards phosphatidylcholine and triglyceride synthesis. Hepatology 58(4), 1296-1305 (2013).
11. Mato JM, Lu SC. Where are we in the search for non- invasive nonalcoholic steatohepatitis biomarkers? Hepatology 54(4), 1115-1117 (2011).
12. Puri P, Wiest MM, Cheung O et al. The plasma lipidomic signature of non-alcoholic steatohepatitis. Hepatology 50(6), 1827-1838 (2009).
13. Kim JY, Park JY, Kim OY et al. Metabolic profiling of plasma in overweight/obese and lean men using ultra performance liquid chromatography and Q-TOF mass spectrometry (UPLC-Q-TOF MS). J. Proteome Res. (9), 4368-4375 (2010).
14. Zhang A, Sun H, Wang X. Power of metabolomics in biomarker discovery and mining mechanisms of obesity. Obes. Rev. 14(4), 344-349 (2012).
15. Kalhan SC, Guo L, Edmison J et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metab. Clin. Exp. 60(3), 404-413 (2011).
16. Barr J, Vázquez-Chantada M, Alonso C et al. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J. Proteome Res. 9(9), 4501-4512 (2010).
17. Barr J, Caballería J, Martínez- Arranz I et al. Obesity- dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J. Proteome Res. 11(4), 2521-2532 (2012).
18. Tokushige K, Hashimoto E, Kodama K et al. Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease. J. Gastroenterol. doi:10.1007/s00535-013- 0766-5 (2013) (Epub ahead of print).